PMID- 23792609
OWN - NLM
STAT- MEDLINE
DCOM- 20140218
LR  - 20181030
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 23
IP  - 6
DP  - 2013 Jul
TI  - Preference-based utility scores for adverse events associated with the treatment 
      of gynecologic cancers.
PG  - 1158-66
LID - 10.1097/IGC.0b013e318299e2a6 [doi]
AB  - OBJECTIVE: Our goals were to (1) define a set of descriptive health states 
      related to adverse events (AEs) associated with gynecologic cancer treatment with 
      radical surgery and chemoradiation and (2) derive a set of quality of 
      life-related utility scores corresponding to these health states. METHODS: We 
      developed a list of health states for grade 3/4 AEs related to gynecologic cancer 
      treatment. Using the visual analog scale score and time trade-off (TTO) methods, 
      valuation of each health state was obtained through interviews of 60 volunteers 
      (15 cervical cancer survivors treated with surgery and/or chemoradiation and 45 
      women without a cancer diagnosis). Health states were ranked by mean/median TTO 
      scores. Wilcoxon rank sum test was used to compare central tendencies related to 
      patient and volunteer characteristics. RESULTS: Patients and volunteers agreed on 
      their preference rankings, with highest preference given to infection (median TTO 
      = 1.0) and thrombosis (median TTO = 0.97). Lowest preference was assigned to 
      radiation proctitis (median TTO = 0.87) and gastrointestinal fistula formation 
      (median TTO = 0.83). Utility scores for the majority of health states were not 
      significantly associated with age, race, parity, patient or volunteer status, 
      history of abnormal Pap smear, stage of cervical cancer diagnosis, or personal 
      experience of a serious treatment-related AE. CONCLUSIONS: This study helps 
      establish preferences and quality-of-life utility scores for health states 
      related to toxicities from surgery, radiation, and chemotherapy for gynecologic 
      cancer treatment. Such information can be used to inform medical decision 
      making/counseling and may be applied to future comparative effectiveness models 
      in which radical surgery and/or chemoradiation are considered.
FAU - Jewell, Elizabeth L
AU  - Jewell EL
AD  - Division of Gynecology, Department of Surgery, Memorial Sloan-Kettering Cancer 
      Center, New York, NY, USA. jewelle@mskcc.org
FAU - Smrtka, Michael
AU  - Smrtka M
FAU - Broadwater, Gloria
AU  - Broadwater G
FAU - Valea, Fidel
AU  - Valea F
FAU - Davis, Debra M
AU  - Davis DM
FAU - Nolte, Kimberly C
AU  - Nolte KC
FAU - Valea, Renea
AU  - Valea R
FAU - Myers, Evan R
AU  - Myers ER
FAU - Havrilesky, Laura J
AU  - Havrilesky LJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/*diagnosis/etiology
MH  - Combined Modality Therapy/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Genital Neoplasms, Female/complications/*therapy
MH  - *Health Status Indicators
MH  - Humans
MH  - Middle Aged
MH  - Pelvic Neoplasms/complications/*therapy
MH  - Prognosis
MH  - *Quality of Life
MH  - Social Perception
MH  - Urinary Bladder Diseases/*diagnosis/etiology
MH  - Young Adult
EDAT- 2013/06/26 06:00
MHDA- 2014/02/19 06:00
CRDT- 2013/06/25 06:00
PHST- 2013/06/25 06:00 [entrez]
PHST- 2013/06/26 06:00 [pubmed]
PHST- 2014/02/19 06:00 [medline]
AID - 00009577-201307000-00030 [pii]
AID - 10.1097/IGC.0b013e318299e2a6 [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2013 Jul;23(6):1158-66. doi: 10.1097/IGC.0b013e318299e2a6.